Prime determinants of serum phosphorus level in hemodialysis patients  by unknown
Kidney Res Clin Pract 33 (2014) 116–117journal homepage: http://www.krcp-ksn.com
Kidney Research and Clinical Practice2211-9
license
http://Contents lists available at ScienceDirectLetter and ReplyPrime determinants of serum phosphorus level in hemodialysis
patientsTo the Editor,
The concept that hyperphosphatemia in hemodialysis
(HD) patients is a risk factor for various outcomes has now
been widely accepted. Many patients on maintenance HD
with a high serum phosphorus level are linked to the
development of aspects of chronic kidney disease-mineral
and bone disorder; they are thus recommended to maintain
serum phosphorus level within a normal range [1]. In order to
control this, we have options such as dietary restriction and
the use of phosphate binders. However, more than half of
patients did not reach the target range in the United States,
Europe, and Japan [2], and the proportion of patients with
hyperphosphatemia may be similar in Korea because the
mean serum phosphorus level was reported to be
5.1471.64 mg/dL [3].
Rhee et al [4] reported that the factors associated with
phosphate control were different depending on the residual
renal function status in Korean patients on maintenance HD.
They also emphasized the preservation of residual renal
function for the optimal phosphorus control in non-anuric
patients. Although I totally agree with the ﬁndings of the
study, it could not be overlooked that we have only a couple of
ways to preserve residual renal function in HD patients,
including the use of ultrapure dialysate, biocompatible mem-
branes, avoiding nephrotoxic drugs, decreasing dialysis fre-
quency, and/or avoidance of aggressive water removal [5].
Therefore, I would like to point out that dietary phosphate
restriction with appropriate protein intake could be the ﬁrst
strategy for controlling serum phosphorus levels in HD
patients. In this regard, as the authors mentioned in the
limitations of the study [4], controlling the amount of dietary
phosphate may not only be important in designing clinical
research, but could also be crucial in the treatment of HD
patients with hyperphosphatemia.
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We appreciate your interest in our recent article entitled
“Signiﬁcance of residual renal function for phosphate control
in chronic hemodialysis patients”. Phosphate is the key reg-
ulator in the chronic kidney disease-mineral bone disease,
which is deeply associated with the cardiovascular outcome in
chronic hemodialysis patients. In the normal physiologic state,
increasing serum phosphate concentration induces secretion
of parathyroid hormone and ﬁbroblast growth factor 23
(FGF-23). These two phosphaturic hormones reduce expression
of sodium-dependent phosphate co-transporters in the prox-
imal tubules, thereby diminishing phosphate reabsorption and
increasing urinary phosphate excretion [1]. However, in end
stage renal disease state, phosphaturia is signiﬁcantly dimin-
ished because of failure in glomerular ﬁltration, even though
the amount of increase of parathyroid hormone or FGF-23 is
considerable. Thus, as our study [2] pointed out, residual renal
function must be the prime determinant of serum phosphate
control in end stage renal disease patients [3].lished by Elsevier. This is an open access article under the CC BY-NC-ND
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management of elevated serum phosphate is still dietary
phosphate restriction along with oral phosphate binder even
in chronic hemodialysis patient, and the current Kidney
Disease Improving Global Outcomes guidelines recommended
limiting dietary phosphate intakes as a ﬁrst line therapy for
the treatment of hyperphosphatemia [4]. Also, in several
previous studies [5,6], restricting dietary phosphate alone
successfully decreased serum FGF-23 levels in patients with
chronic kidney disease. However considering that phosphate-
rich foods tend to be good sources of dietary protein, long-
term restriction of phosphate might lead to protein–energy
malnutrition. In fact, in the study by Lynch et al [7], prescribed
dietary phosphate restriction is not associated with improved
survival among prevalent hemodialysis patients, and increased
level of restriction may be associated with greater mortality in
some subgroups. Thus, we believe that, balancing between
phosphate restriction and sufﬁcient protein–energy supple-
ment is the most important aspect in the management of
chronic hemodialysis patients.Conﬂicts of interest
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